Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy—— AKT/m-TOR Pathway and Resistance to Cancer Therapy

Liudmila V SPIRINA; Irina V KONDAKOVA; Natalia V TARASENKO; Elena M SLONIMSKAYA; Evgeny A USYNIN; Alexey K GORBUNOV; Zahar A YURMAZOV; Svetlana Yu CHIGEVSKAYA

doi:10.3779/j.issn.1009-3419.2018.01.09

Chinese Journal of Lung Cancer (Jan 2018)

Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy—— AKT/m-TOR Pathway and Resistance to Cancer Therapy

Liudmila V SPIRINA,
Irina V KONDAKOVA,
Natalia V TARASENKO,
Elena M SLONIMSKAYA,
Evgeny A USYNIN,
Alexey K GORBUNOV,
Zahar A YURMAZOV,
Svetlana Yu CHIGEVSKAYA

Affiliations

Liudmila V SPIRINA: Laboratory of Tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Russia
Irina V KONDAKOVA: Laboratory of Tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Russia
Natalia V TARASENKO: Department of Medical Genetics, Siberian State Medical University, Tomsk, Russia
Elena M SLONIMSKAYA: Surgical Department, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Russia
Evgeny A USYNIN: Surgical Department, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Russia
Alexey K GORBUNOV: Surgical Department, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Russia
Zahar A YURMAZOV: Surgical Department, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Russia
Svetlana Yu CHIGEVSKAYA: Surgical Department, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Russia

DOI: https://doi.org/10.3779/j.issn.1009-3419.2018.01.09
Journal volume & issue: Vol. 21, no. 1
pp. 63 – 66

Abstract

Read online

Resistance to cancer therapy continues to be a major limitation for the successful treatment of cancer. There are many published studies on therapy resistance in breast and prostate cancers; however, there are currently no data on molecular markers associated with resistance. The conflicting data were reported regarding the AKT/m-TOR signaling pathway components as markers predicting resistance. The AKT/m-TOR signaling pathway is involved in the development of many human cancers; its activation is related to cell proliferation, angiogenesis, apoptosis, as well as to therapy resistance. Molecular alterations in the AKT/m-TOR signaling pathway provide a platform to identify universal markers associated with the development of resistance to cancer therapy.

Published in Chinese Journal of Lung Cancer

ISSN: 1009-3419 (Print); 1999-6187 (Online)
Publisher: Chinese Anti-Cancer Association; Chinese Antituberculosis Association
Country of publisher: China
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.lungca.org

About the journal

Abstract

Keywords